The competitive landscape for PD-(L)1xVEGF bispecifics is finally taking shape.
For the last couple years, much of the attention has focused on Summit Therapeutics and its lead drug ivonescimab. Now, two other challengers are revving …
Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the
Advances in therapeutics are outpacing the development of diagnostics due to policy and payment barriers, holding back effective, targeted care.
→ A decorated GLP-1 pioneer is retiring at Novo Nordisk. Channeling Elvis Presley with a microphone emoji for good measure, Lotte Bjerre Knudsen said on
A landmark study in China has shown that a base-editing therapy developed by CorrectSequence achieved stellar results in beta-thalassaemia.
Oricell Therapeutics has raised more than $110 million in what it calls a pre-IPO financing. The company is developing CAR-T therapies for solid tumors, including
The competitive landscape for PD-(L)1xVEGF bispecifics is finally taking shape.
For the last couple years, much of the attention has focused on Summit Therapeutics and its lead drug ivonescimab. Now, two other challengers are revving …